Prevent-HF – For Patients with an Increased Risk of Developing Heart Failure

  • Study Sponsor and Protocol Number: 
    AstraZeneca / D6973C00001
  • Specialty:
    Internal Medicine / Cardiology
  • Type:
    Investigational Drug in combination with a known medication (Dapagliflozin)
  • Inclusion:
    Type 2 diabetes
    Hypertension
    At least one additional risk factor (as defined by protocol)
  • Exclusion:
    Previously diagnosed
    Type 1 diabetes
    Hyperkalaemia
    Recent stroke or heart attack